- Home
- LXEH vs ADTX Comparison
LXEH vs ADTX Comparison
Compare LXEH & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- ADTX
- Stock Information
- Founded
- LXEH 2001
- ADTX 2017
- Country
- LXEH China
- ADTX United States
- Employees
- LXEH N/A
- ADTX N/A
- Industry
- LXEH Other Consumer Services
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- ADTX Health Care
- Exchange
- LXEH Nasdaq
- ADTX Nasdaq
- Market Cap
- LXEH 5.7M
- ADTX 5.3M
- IPO Year
- LXEH 2020
- ADTX 2020
- Fundamental
- Price
- LXEH $4.92
- ADTX $0.13
- Analyst Decision
- LXEH
- ADTX
- Analyst Count
- LXEH 0
- ADTX 0
- Target Price
- LXEH N/A
- ADTX N/A
- AVG Volume (30 Days)
- LXEH 105.0K
- ADTX 39.3M
- Earning Date
- LXEH 03-15-2025
- ADTX 11-18-2024
- Dividend Yield
- LXEH N/A
- ADTX N/A
- EPS Growth
- LXEH N/A
- ADTX N/A
- EPS
- LXEH N/A
- ADTX N/A
- Revenue
- LXEH $5,628,870.00
- ADTX $212,107.00
- Revenue This Year
- LXEH N/A
- ADTX $95.61
- Revenue Next Year
- LXEH N/A
- ADTX $1,584.79
- P/E Ratio
- LXEH N/A
- ADTX N/A
- Revenue Growth
- LXEH N/A
- ADTX N/A
- 52 Week Low
- LXEH $1.95
- ADTX $0.12
- 52 Week High
- LXEH $65.06
- ADTX $218.00
- Technical
- Relative Strength Index (RSI)
- LXEH 53.73
- ADTX 18.05
- Support Level
- LXEH $4.70
- ADTX $0.12
- Resistance Level
- LXEH $5.45
- ADTX $0.21
- Average True Range (ATR)
- LXEH 0.51
- ADTX 0.03
- MACD
- LXEH -0.14
- ADTX 0.03
- Stochastic Oscillator
- LXEH 26.64
- ADTX 9.91
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.